Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOV-2301
- Development stage
- Unknown
- Lead developer
- CombinatoRx
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
FOV-2301 is a small molecule drug initially developed by Zalicus, Inc. It is under research primarily for therapeutic areas including cardiovascular diseases, endocrinology and metabolic diseases, and eye diseases. The drug has been investigated for indications such as diabetic retinopathy. Its current highest research and development status is pending, indicating it has not yet reached advanced clinical trial phases or approval. Specific mechanisms of action are not detailed in the available data.
- Other names
- FOV-2301FOV2301FOV 2301
Beyond the preview
Go deeper on FOV-2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOV-2301.